Histoplasmosis clinical trials at UC Davis

1 research study open to eligible people

Open-Label Study to Evaluate Efficacy and Safety of Ibrexafungerp in Patients With Refractory or Intolerant Fungal Diseases
open to eligible people ages 18 years and up
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
Sacramento, California and other locations

Last updated: January 2023

Open-Label Study to Evaluate Efficacy and Safety of Ibrexafungerp in Patients With Refractory or Intolerant Fungal Diseases